Chromium(III) picolinate / CrPic

evidence_span

{"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"}

experimental_model

Hyperinsulinemia model with AMPK silencing

exposure

Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA

limitations

Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat L6 skeletal muscle myotubes

plain_language

The response involved the cell’s energy-sensing pathway rather than a measured increase in proximal insulin signaling.

primary_references

[chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

tissue_or_cell_type

Cultured muscle plasma membrane and cortical actin

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 354–365

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Hyperinsulinemia model with AMPK silencing · source_derived_draft · unverified_draft

### chromium-ampk-response Chromium picolinate increased AMPK signaling in L6 myotubes without enhancing the proximal insulin-signaling responses measured in that experiment. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The response involved the cell’s energy-sensing pathway rather than a measured increase in proximal insulin signaling. organism: Rat L6 skeletal muscle myotubes tissue_or_cell_type: Cultured muscle plasma membrane and cortical actin experimental_model: Hyperinsulinemia model with AMPK silencing limitations: Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment. exposure: Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA evidence_span: {"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"} [chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

evidence_span

{"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"}

experimental_model

Randomized double-blind placebo-controlled combination trial; 447 enrolled

exposure

600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication

limitations

There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with poorly controlled type 2 diabetes

plain_language

The combination also improved fasting glucose in this trial.

primary_references

[chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

tissue_or_cell_type

HbA1c and fasting glucose

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 705–716

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled combination trial; 447 enrolled · source_derived_draft · unverified_draft

### chromium-biotin-combination-glucose Fasting glucose changed by −9.8 mg/dL with chromium picolinate plus biotin versus +0.7 mg/dL with placebo (p=0.02). Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combination also improved fasting glucose in this trial. organism: Human with poorly controlled type 2 diabetes tissue_or_cell_type: HbA1c and fasting glucose experimental_model: Randomized double-blind placebo-controlled combination trial; 447 enrolled limitations: There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited. exposure: 600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication evidence_span: {"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"} [chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

evidence_span

{"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"}

experimental_model

Randomized double-blind placebo-controlled combination trial; 447 enrolled

exposure

600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication

limitations

There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with poorly controlled type 2 diabetes

plain_language

The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.

primary_references

[chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

tissue_or_cell_type

HbA1c and fasting glucose

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 692–703

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled combination trial; 447 enrolled · source_derived_draft · unverified_draft

### chromium-biotin-combination-hba1c The combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved. organism: Human with poorly controlled type 2 diabetes tissue_or_cell_type: HbA1c and fasting glucose experimental_model: Randomized double-blind placebo-controlled combination trial; 447 enrolled limitations: There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited. exposure: 600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication evidence_span: {"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"} [chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

evidence_span

{"source_cache": "artifacts/chromium-research/20721637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "550ce1e2898494fb6f385c11a446c6516812bffacefc4c78161fbee16adfc39f", "start_char": 0, "end_char": 1671, "text_sha256": "550ce1e2898494fb6f385c11a446c6516812bffacefc4c78161fbee16adfc39f"}

experimental_model

Transporter localization and substrate-uptake assays

exposure

Insulin, chromium picolinate and wortmannin comparisons

limitations

Membrane localization is not equivalent to transporter activity. CD36 trafficking responses to insulin and chromium were not additive; results do not show a general increase in beneficial fatty-acid disposal.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse 3T3-L1 adipocytes

plain_language

Chromium affected a fatty-acid transporter as well as GLUT4, with a different response pattern.

primary_references

[chromium-p20721637] Insulin and chromium picolinate induce translocation of CD36 to the plasma membrane through different signaling pathways in 3T3-L1 adipocytes, and with a differential functionality of the CD36. (2011). https://pubmed.ncbi.nlm.nih.gov/20721637/ DOI: 10.1007/s12011-010-8809-8

tissue_or_cell_type

Plasma membrane

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 458–469

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Transporter localization and substrate-uptake assays · source_derived_draft · unverified_draft

### chromium-cd36-trafficking Chromium picolinate increased plasma-membrane CD36 localization in 3T3-L1 adipocytes; combining it with insulin did not produce additive CD36 translocation. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Chromium affected a fatty-acid transporter as well as GLUT4, with a different response pattern. organism: Mouse 3T3-L1 adipocytes tissue_or_cell_type: Plasma membrane experimental_model: Transporter localization and substrate-uptake assays limitations: Membrane localization is not equivalent to transporter activity. CD36 trafficking responses to insulin and chromium were not additive; results do not show a general increase in beneficial fatty-acid disposal. exposure: Insulin, chromium picolinate and wortmannin comparisons evidence_span: {"source_cache": "artifacts/chromium-research/20721637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "550ce1e2898494fb6f385c11a446c6516812bffacefc4c78161fbee16adfc39f", "start_char": 0, "end_char": 1671, "text_sha256": "550ce1e2898494fb6f385c11a446c6516812bffacefc4c78161fbee16adfc39f"} [chromium-p20721637] Insulin and chromium picolinate induce translocation of CD36 to the plasma membrane through different signaling pathways in 3T3-L1 adipocytes, and with a differential functionality of the CD36. (2011). https://pubmed.ncbi.nlm.nih.gov/20721637/ DOI: 10.1007/s12011-010-8809-8

evidence_span

{"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"}

experimental_model

GLUT4 trafficking, glucose uptake and cholesterol add-back experiments

exposure

Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation

limitations

Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse 3T3-L1 adipocytes

plain_language

Putting cholesterol back into the membrane removed the effect, supporting a membrane-dependent mechanism.

primary_references

[chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

tissue_or_cell_type

Cultured adipocyte plasma membrane

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 328–339

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · GLUT4 trafficking, glucose uptake and cholesterol add-back experiments · source_derived_draft · unverified_draft

### chromium-cholesterol-dependent-uptake Chromium-associated membrane-cholesterol reduction accompanied enhanced insulin-stimulated glucose uptake, and cholesterol add-back prevented the trafficking and uptake benefit. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Putting cholesterol back into the membrane removed the effect, supporting a membrane-dependent mechanism. organism: Mouse 3T3-L1 adipocytes tissue_or_cell_type: Cultured adipocyte plasma membrane experimental_model: GLUT4 trafficking, glucose uptake and cholesterol add-back experiments limitations: Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found. exposure: Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation evidence_span: {"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"} [chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

evidence_span

{"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"}

experimental_model

Hyperinsulinemia model with AMPK silencing

exposure

Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA

limitations

Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat L6 skeletal muscle myotubes

plain_language

The cell’s supporting actin structure was better preserved under the tested conditions.

primary_references

[chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

tissue_or_cell_type

Cultured muscle plasma membrane and cortical actin

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 380–391

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Hyperinsulinemia model with AMPK silencing · source_derived_draft · unverified_draft

### chromium-cortical-actin-protection Chromium picolinate protected L6 myotubes from hyperinsulinemia-associated cortical filamentous-actin loss. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The cell’s supporting actin structure was better preserved under the tested conditions. organism: Rat L6 skeletal muscle myotubes tissue_or_cell_type: Cultured muscle plasma membrane and cortical actin experimental_model: Hyperinsulinemia model with AMPK silencing limitations: Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment. exposure: Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA evidence_span: {"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"} [chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

evidence_span

{"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"}

experimental_model

Randomized three-arm supplementation trial; 180 adults

exposure

Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued

limitations

Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with treated type 2 diabetes

plain_language

Fasting glucose was also lower in the higher-dose group.

primary_references

[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

tissue_or_cell_type

HbA1c, glucose, insulin and lipids

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1030–1041

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized three-arm supplementation trial; 180 adults · source_derived_draft · unverified_draft

### chromium-diabetes-fasting-glucose-positive The 1,000 µg/day group had lower fasting glucose than placebo at two and four months; four-month values were 7.1 versus 8.8 mmol/L. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Fasting glucose was also lower in the higher-dose group. organism: Human with treated type 2 diabetes tissue_or_cell_type: HbA1c, glucose, insulin and lipids experimental_model: Randomized three-arm supplementation trial; 180 adults limitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects. exposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued evidence_span: {"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"} [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

evidence_span

{"source_cache": "artifacts/chromium-research/16505499.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59", "start_char": 0, "end_char": 1206, "text_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59"}

experimental_model

Six-month double-blind randomized placebo-controlled trial

exposure

500 or 1,000 µg Cr/day as picolinate; baseline HbA1c >8% and insulin >50 units/day; per-protocol analysis n=46

limitations

Per-protocol analysis and selected insulin-treated population. This is a clinically relevant null result, not proof that no person can respond.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human obese adults with insulin-treated type 2 diabetes

plain_language

A later trial did not reproduce the earlier glucose-control benefit.

primary_references

[chromium-p16505499] Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16505499/ DOI: 10.2337/diacare.29.03.06.dc05-1453

tissue_or_cell_type

HbA1c and secondary metabolic endpoints

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1056–1067

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-month double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft

### chromium-diabetes-hba1c-null HbA1c fell by about 0.4 percentage points in all three groups, with no chromium benefit over placebo. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A later trial did not reproduce the earlier glucose-control benefit. organism: Human obese adults with insulin-treated type 2 diabetes tissue_or_cell_type: HbA1c and secondary metabolic endpoints experimental_model: Six-month double-blind randomized placebo-controlled trial limitations: Per-protocol analysis and selected insulin-treated population. This is a clinically relevant null result, not proof that no person can respond. exposure: 500 or 1,000 µg Cr/day as picolinate; baseline HbA1c >8% and insulin >50 units/day; per-protocol analysis n=46 evidence_span: {"source_cache": "artifacts/chromium-research/16505499.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59", "start_char": 0, "end_char": 1206, "text_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59"} [chromium-p16505499] Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16505499/ DOI: 10.2337/diacare.29.03.06.dc05-1453

evidence_span

{"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"}

experimental_model

Randomized three-arm supplementation trial; 180 adults

exposure

Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued

limitations

Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with treated type 2 diabetes

plain_language

This trial reported better long-term glucose control with chromium picolinate.

primary_references

[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

tissue_or_cell_type

HbA1c, glucose, insulin and lipids

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1017–1028

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized three-arm supplementation trial; 180 adults · source_derived_draft · unverified_draft

### chromium-diabetes-hba1c-positive After four months, reported HbA1c values were 8.5%, 7.5% and 6.6% in the placebo, 200 µg/day and 1,000 µg/day groups, respectively. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This trial reported better long-term glucose control with chromium picolinate. organism: Human with treated type 2 diabetes tissue_or_cell_type: HbA1c, glucose, insulin and lipids experimental_model: Randomized three-arm supplementation trial; 180 adults limitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects. exposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued evidence_span: {"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"} [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

evidence_span

{"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"}

experimental_model

Randomized three-arm supplementation trial; 180 adults

exposure

Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued

limitations

Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with treated type 2 diabetes

plain_language

The study reported an insulin change alongside its glucose findings.

primary_references

[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

tissue_or_cell_type

HbA1c, glucose, insulin and lipids

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1043–1054

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized three-arm supplementation trial; 180 adults · source_derived_draft · unverified_draft

### chromium-diabetes-insulin-positive Fasting and two-hour insulin measurements decreased in both chromium-supplemented groups in the reported study. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The study reported an insulin change alongside its glucose findings. organism: Human with treated type 2 diabetes tissue_or_cell_type: HbA1c, glucose, insulin and lipids experimental_model: Randomized three-arm supplementation trial; 180 adults limitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects. exposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued evidence_span: {"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"} [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

evidence_span

{"source_cache": "artifacts/chromium-research/16873787.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c", "start_char": 0, "end_char": 1823, "text_sha256": "e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c"}

experimental_model

Double-blind randomized trial after sulfonylurea run-in

exposure

Glipizide run-in then 1,000 µg Cr/day as picolinate or placebo for six months; randomized groups n=17 and n=12

limitations

Small trial with concurrent glipizide. Reported benefit does not establish chromium deficiency, isolate every mediator or generalize to other treatment populations.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with type 2 diabetes

plain_language

This smaller trial reported benefit in a different medication setting.

primary_references

[chromium-p16873787] Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. (2006). https://pubmed.ncbi.nlm.nih.gov/16873787/ DOI: 10.2337/dc06-0254

tissue_or_cell_type

Insulin sensitivity, glycated hemoglobin and body composition

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1069–1080

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized trial after sulfonylurea run-in · source_derived_draft · unverified_draft

### chromium-glipizide-trial-sensitivity The chromium-plus-sulfonylurea group showed improved measured insulin sensitivity and glucose control compared with the study’s sulfonylurea/placebo comparison. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This smaller trial reported benefit in a different medication setting. organism: Human with type 2 diabetes tissue_or_cell_type: Insulin sensitivity, glycated hemoglobin and body composition experimental_model: Double-blind randomized trial after sulfonylurea run-in limitations: Small trial with concurrent glipizide. Reported benefit does not establish chromium deficiency, isolate every mediator or generalize to other treatment populations. exposure: Glipizide run-in then 1,000 µg Cr/day as picolinate or placebo for six months; randomized groups n=17 and n=12 evidence_span: {"source_cache": "artifacts/chromium-research/16873787.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c", "start_char": 0, "end_char": 1823, "text_sha256": "e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c"} [chromium-p16873787] Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. (2006). https://pubmed.ncbi.nlm.nih.gov/16873787/ DOI: 10.2337/dc06-0254

evidence_span

{"source_cache": "artifacts/chromium-research/9322572.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8", "start_char": 0, "end_char": 1869, "text_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8"}

experimental_model

Randomized double-blind supplementation with resistance training; 18 men

exposure

924 µg chromium/day as picolinate versus placebo for 12 weeks; nine men/group

limitations

Small selected population and short follow-up. A negative result does not exclude every interaction in iron-deficient people or other exposures.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human men aged 56–69

plain_language

The proposed iron-depleting effect was not observed in these older men.

primary_references

[chromium-p9322572] Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. (1997). https://pubmed.ncbi.nlm.nih.gov/9322572/ DOI: 10.1093/ajcn/66.4.944

tissue_or_cell_type

Iron-status and hematologic indices

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 536–547

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind supplementation with resistance training; 18 men · source_derived_draft · unverified_draft

### chromium-human-iron-status-null Chromium picolinate did not change the measured hematologic indices, serum iron or ferritin relative to placebo during the training study. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The proposed iron-depleting effect was not observed in these older men. organism: Human men aged 56–69 tissue_or_cell_type: Iron-status and hematologic indices experimental_model: Randomized double-blind supplementation with resistance training; 18 men limitations: Small selected population and short follow-up. A negative result does not exclude every interaction in iron-deficient people or other exposures. exposure: 924 µg chromium/day as picolinate versus placebo for 12 weeks; nine men/group evidence_span: {"source_cache": "artifacts/chromium-research/9322572.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8", "start_char": 0, "end_char": 1869, "text_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8"} [chromium-p9322572] Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. (1997). https://pubmed.ncbi.nlm.nih.gov/9322572/ DOI: 10.1093/ajcn/66.4.944

evidence_span

{"source_cache": "artifacts/chromium-research/9322572.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8", "start_char": 0, "end_char": 1869, "text_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8"}

experimental_model

Randomized double-blind supplementation with resistance training; 18 men

exposure

924 µg chromium/day as picolinate versus placebo for 12 weeks; nine men/group

limitations

Small selected population and short follow-up. A negative result does not exclude every interaction in iron-deficient people or other exposures.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human men aged 56–69

plain_language

Sharing carrier chemistry did not translate into a detectable adverse iron-transport effect in this trial.

primary_references

[chromium-p9322572] Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. (1997). https://pubmed.ncbi.nlm.nih.gov/9322572/ DOI: 10.1093/ajcn/66.4.944

tissue_or_cell_type

Iron-status and hematologic indices

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 549–560

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind supplementation with resistance training; 18 men · source_derived_draft · unverified_draft

### chromium-human-transferrin-saturation-null Chromium picolinate did not alter the training-associated changes in total iron-binding capacity or transferrin saturation. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Sharing carrier chemistry did not translate into a detectable adverse iron-transport effect in this trial. organism: Human men aged 56–69 tissue_or_cell_type: Iron-status and hematologic indices experimental_model: Randomized double-blind supplementation with resistance training; 18 men limitations: Small selected population and short follow-up. A negative result does not exclude every interaction in iron-deficient people or other exposures. exposure: 924 µg chromium/day as picolinate versus placebo for 12 weeks; nine men/group evidence_span: {"source_cache": "artifacts/chromium-research/9322572.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8", "start_char": 0, "end_char": 1869, "text_sha256": "767fd4144862b2bbc3bf416541442924fc69da030435898b1e6843dba8e35dc8"} [chromium-p9322572] Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. (1997). https://pubmed.ncbi.nlm.nih.gov/9322572/ DOI: 10.1093/ajcn/66.4.944

evidence_span

{"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"}

experimental_model

C2C12 cell experiments with supporting database pathway analysis

exposure

Chromium picolinate, ferric ammonium citrate and combination

limitations

Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse C2C12 skeletal-muscle cells

plain_language

The chromium compound partly countered an iron-induced glucose-uptake defect in cultured cells.

primary_references

[chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

tissue_or_cell_type

Cellular glucose uptake, ROS assays and signaling proteins

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 770–781

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · C2C12 cell experiments with supporting database pathway analysis · source_derived_draft · unverified_draft

### chromium-iron-cell-glucose Chromium picolinate plus ferric ammonium citrate produced greater insulin-stimulated glucose uptake than ferric ammonium citrate alone in C2C12 cells. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The chromium compound partly countered an iron-induced glucose-uptake defect in cultured cells. organism: Mouse C2C12 skeletal-muscle cells tissue_or_cell_type: Cellular glucose uptake, ROS assays and signaling proteins experimental_model: C2C12 cell experiments with supporting database pathway analysis limitations: Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested. exposure: Chromium picolinate, ferric ammonium citrate and combination evidence_span: {"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"} [chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

evidence_span

{"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"}

experimental_model

C2C12 cell experiments with supporting database pathway analysis

exposure

Chromium picolinate, ferric ammonium citrate and combination

limitations

Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse C2C12 skeletal-muscle cells

plain_language

The glucose transporter and measured signaling steps were less suppressed.

primary_references

[chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

tissue_or_cell_type

Cellular glucose uptake, ROS assays and signaling proteins

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 796–807

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · C2C12 cell experiments with supporting database pathway analysis · source_derived_draft · unverified_draft

### chromium-iron-cell-glut4 Chromium co-treatment increased GLUT4 levels relative to the iron-only condition, alongside higher PI3K and Akt phosphorylation ratios. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The glucose transporter and measured signaling steps were less suppressed. organism: Mouse C2C12 skeletal-muscle cells tissue_or_cell_type: Cellular glucose uptake, ROS assays and signaling proteins experimental_model: C2C12 cell experiments with supporting database pathway analysis limitations: Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested. exposure: Chromium picolinate, ferric ammonium citrate and combination evidence_span: {"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"} [chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

evidence_span

{"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"}

experimental_model

C2C12 cell experiments with supporting database pathway analysis

exposure

Chromium picolinate, ferric ammonium citrate and combination

limitations

Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse C2C12 skeletal-muscle cells

plain_language

A measured oxidative-stress signal was lower with co-treatment.

primary_references

[chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

tissue_or_cell_type

Cellular glucose uptake, ROS assays and signaling proteins

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 783–794

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · C2C12 cell experiments with supporting database pathway analysis · source_derived_draft · unverified_draft

### chromium-iron-cell-ros The combination had a lower intracellular ROS assay signal than ferric ammonium citrate alone. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A measured oxidative-stress signal was lower with co-treatment. organism: Mouse C2C12 skeletal-muscle cells tissue_or_cell_type: Cellular glucose uptake, ROS assays and signaling proteins experimental_model: C2C12 cell experiments with supporting database pathway analysis limitations: Pathway databases generate hypotheses. Co-changing ROS and signaling measurements do not alone establish a unique causal sequence; no human iron-overload treatment was tested. exposure: Chromium picolinate, ferric ammonium citrate and combination evidence_span: {"source_cache": "artifacts/chromium-research/37156991.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda", "start_char": 0, "end_char": 1621, "text_sha256": "e5b7952975edd461bc01f9a4389588789a7d1b7dedf56fb97270051092ae6cda"} [chromium-p37156991] Antagonizing Effects of Chromium Against Iron-Decreased Glucose Uptake by Regulating ROS-Mediated PI3K/Akt/GLUT4 Signaling Pathway in C2C12. (2024). https://pubmed.ncbi.nlm.nih.gov/37156991/ DOI: 10.1007/s12011-023-03695-z

evidence_span

{"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"}

experimental_model

Five-group iron-excess supplementation experiment; 30 rats

exposure

Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels

limitations

Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Wistar rats

plain_language

A measured component of the cell-death response was lower.

primary_references

[chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

tissue_or_cell_type

Pancreatic tissue and systemic glucose measures

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 835–846

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Five-group iron-excess supplementation experiment; 30 rats · source_derived_draft · unverified_draft

### chromium-iron-rat-bax Chromium treatment countered the iron-associated increase in pancreatic Bax. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A measured component of the cell-death response was lower. organism: Male Wistar rats tissue_or_cell_type: Pancreatic tissue and systemic glucose measures experimental_model: Five-group iron-excess supplementation experiment; 30 rats limitations: Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim. exposure: Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels evidence_span: {"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"} [chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

evidence_span

{"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"}

experimental_model

Five-group iron-excess supplementation experiment; 30 rats

exposure

Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels

limitations

Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Wistar rats

plain_language

A protein associated with cell survival was better preserved.

primary_references

[chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

tissue_or_cell_type

Pancreatic tissue and systemic glucose measures

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 822–833

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Five-group iron-excess supplementation experiment; 30 rats · source_derived_draft · unverified_draft

### chromium-iron-rat-bcl2 Chromium treatment countered the iron-associated reduction in pancreatic Bcl-2. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A protein associated with cell survival was better preserved. organism: Male Wistar rats tissue_or_cell_type: Pancreatic tissue and systemic glucose measures experimental_model: Five-group iron-excess supplementation experiment; 30 rats limitations: Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim. exposure: Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels evidence_span: {"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"} [chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

evidence_span

{"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"}

experimental_model

Five-group iron-excess supplementation experiment; 30 rats

exposure

Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels

limitations

Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Wistar rats

plain_language

The iron-challenged rats showed less pancreatic-cell injury with chromium treatment.

primary_references

[chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

tissue_or_cell_type

Pancreatic tissue and systemic glucose measures

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 809–820

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Five-group iron-excess supplementation experiment; 30 rats · source_derived_draft · unverified_draft

### chromium-iron-rat-beta-cell-apoptosis Chromium picolinate attenuated the pancreatic beta-cell apoptosis associated with iron excess in the rat experiment. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The iron-challenged rats showed less pancreatic-cell injury with chromium treatment. organism: Male Wistar rats tissue_or_cell_type: Pancreatic tissue and systemic glucose measures experimental_model: Five-group iron-excess supplementation experiment; 30 rats limitations: Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim. exposure: Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels evidence_span: {"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"} [chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

evidence_span

{"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"}

experimental_model

Five-group iron-excess supplementation experiment; 30 rats

exposure

Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels

limitations

Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Wistar rats

plain_language

A later component of the cell-death pathway was lower.

primary_references

[chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

tissue_or_cell_type

Pancreatic tissue and systemic glucose measures

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 848–859

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Five-group iron-excess supplementation experiment; 30 rats · source_derived_draft · unverified_draft

### chromium-iron-rat-caspase9 Chromium treatment countered the iron-associated increase in pancreatic cleaved caspase-9. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A later component of the cell-death pathway was lower. organism: Male Wistar rats tissue_or_cell_type: Pancreatic tissue and systemic glucose measures experimental_model: Five-group iron-excess supplementation experiment; 30 rats limitations: Small animal experiment with multiple measured changes. Pathway mediation was proposed, not established by a complete intervention on each signaling node; no human treatment or dietary rescue claim. exposure: Eight weeks; adequate or excessive iron as iron citrate with three chromium-picolinate dose levels evidence_span: {"source_cache": "artifacts/chromium-research/41108476.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3", "start_char": 0, "end_char": 1865, "text_sha256": "7c71767b7a3b58e61b7961f55febf9d637807fe598539f4257a3b1e40fe03fb3"} [chromium-p41108476] Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. (2026). https://pubmed.ncbi.nlm.nih.gov/41108476/ DOI: 10.1007/s12011-025-04867-9

evidence_span

{"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"}

experimental_model

Hyperinsulinemia model with AMPK silencing

exposure

Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA

limitations

Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat L6 skeletal muscle myotubes

plain_language

The treatment prevented a membrane-lipid change associated with insulin resistance in this model.

primary_references

[chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

tissue_or_cell_type

Cultured muscle plasma membrane and cortical actin

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 367–378

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Hyperinsulinemia model with AMPK silencing · source_derived_draft · unverified_draft

### chromium-membrane-cholesterol-protection Chromium picolinate protected hyperinsulinemic L6 myotubes against excess membrane cholesterol. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The treatment prevented a membrane-lipid change associated with insulin resistance in this model. organism: Rat L6 skeletal muscle myotubes tissue_or_cell_type: Cultured muscle plasma membrane and cortical actin experimental_model: Hyperinsulinemia model with AMPK silencing limitations: Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment. exposure: Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA evidence_span: {"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"} [chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

evidence_span

{"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"}

experimental_model

Radiolabeled-compound whole-body counting in rats and a human volunteer

exposure

Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate

limitations

Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat and human; species-specific results retained

plain_language

A compound can enter the body more readily yet leave quickly, without increasing retained chromium.

primary_references

[chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5

tissue_or_cell_type

Intestinal uptake, urine and whole-body retention

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 120–131

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Radiolabeled-compound whole-body counting in rats and a human volunteer · source_derived_draft · unverified_draft

### chromium-picolinate-absorption-retention Rapid urinary loss accounted for much newly absorbed chromium picolinate; in the human comparison, seven-day retention was similarly low for picolinate and phenylalaninate. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A compound can enter the body more readily yet leave quickly, without increasing retained chromium. organism: Rat and human; species-specific results retained tissue_or_cell_type: Intestinal uptake, urine and whole-body retention experimental_model: Radiolabeled-compound whole-body counting in rats and a human volunteer limitations: Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities. exposure: Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate evidence_span: {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"} [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5

evidence_span

{"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"}

experimental_model

GLUT4 trafficking, glucose uptake and cholesterol add-back experiments

exposure

Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation

limitations

Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse 3T3-L1 adipocytes

plain_language

Chromium exposure moved glucose transporters closer to the surface, but insulin was still needed for the functional response.

primary_references

[chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

tissue_or_cell_type

Cultured adipocyte plasma membrane

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 302–313

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · GLUT4 trafficking, glucose uptake and cholesterol add-back experiments · source_derived_draft · unverified_draft

### chromium-picolinate-glut4 The tested picolinate form mobilized GLUT4-containing vesicles toward the cell surface; insulin promoted their incorporation into the plasma membrane. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Chromium exposure moved glucose transporters closer to the surface, but insulin was still needed for the functional response. organism: Mouse 3T3-L1 adipocytes tissue_or_cell_type: Cultured adipocyte plasma membrane experimental_model: GLUT4 trafficking, glucose uptake and cholesterol add-back experiments limitations: Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found. exposure: Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation evidence_span: {"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"} [chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

evidence_span

{"source_cache": "artifacts/chromium-research/20634174.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8a4617886df8215ff55fd78eac2a60d4e63ed726da4f1f1a9167fb9c41ceae26", "start_char": 0, "end_char": 1529, "text_sha256": "8a4617886df8215ff55fd78eac2a60d4e63ed726da4f1f1a9167fb9c41ceae26"}

experimental_model

Randomized double-blind modified crossover trial; 59 enrolled

exposure

Six-month sequences of 500 or 1,000 µg/day chromium picolinate versus placebo

limitations

At-risk population rather than established diabetes; no demonstrated prevention effect. Exposure does not establish the participant’s nutritional chromium status.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human adults at high risk for type 2 diabetes

plain_language

The supplement did not improve the measured insulin-resistance outcomes in this at-risk group.

primary_references

[chromium-p20634174] Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. (2011). https://pubmed.ncbi.nlm.nih.gov/20634174/ DOI: 10.4158/ep10131.or

tissue_or_cell_type

Glucose, insulin, HOMA-IR and secondary cardiometabolic endpoints

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1108–1119

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind modified crossover trial; 59 enrolled · source_derived_draft · unverified_draft

### chromium-prediabetes-null Neither tested dose improved glucose, insulin or HOMA-IR compared with placebo after six months; secondary outcomes also did not improve. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The supplement did not improve the measured insulin-resistance outcomes in this at-risk group. organism: Human adults at high risk for type 2 diabetes tissue_or_cell_type: Glucose, insulin, HOMA-IR and secondary cardiometabolic endpoints experimental_model: Randomized double-blind modified crossover trial; 59 enrolled limitations: At-risk population rather than established diabetes; no demonstrated prevention effect. Exposure does not establish the participant’s nutritional chromium status. exposure: Six-month sequences of 500 or 1,000 µg/day chromium picolinate versus placebo evidence_span: {"source_cache": "artifacts/chromium-research/20634174.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8a4617886df8215ff55fd78eac2a60d4e63ed726da4f1f1a9167fb9c41ceae26", "start_char": 0, "end_char": 1529, "text_sha256": "8a4617886df8215ff55fd78eac2a60d4e63ed726da4f1f1a9167fb9c41ceae26"} [chromium-p20634174] Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. (2011). https://pubmed.ncbi.nlm.nih.gov/20634174/ DOI: 10.4158/ep10131.or

evidence_span

{"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"}

experimental_model

GLUT4 trafficking, glucose uptake and cholesterol add-back experiments

exposure

Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation

limitations

Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Mouse 3T3-L1 adipocytes

plain_language

The transporter effect did not require a bigger response in the insulin-signaling measurements tested here.

primary_references

[chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

tissue_or_cell_type

Cultured adipocyte plasma membrane

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 341–352

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · GLUT4 trafficking, glucose uptake and cholesterol add-back experiments · source_derived_draft · unverified_draft

### chromium-proximal-signaling-not-amplified Chromium-associated GLUT4 trafficking in this study was not accompanied by enhancement of the examined insulin-receptor, IRS-1, PI3K or Akt signaling steps. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The transporter effect did not require a bigger response in the insulin-signaling measurements tested here. organism: Mouse 3T3-L1 adipocytes tissue_or_cell_type: Cultured adipocyte plasma membrane experimental_model: GLUT4 trafficking, glucose uptake and cholesterol add-back experiments limitations: Cell-culture pharmacology does not establish an essential dietary function. Vesicle arrival near the membrane and actual membrane insertion are different observations; no amplification of the tested proximal insulin signals was found. exposure: Chromium(III) chloride or chromium picolinate; insulin stimulation and cholesterol manipulation evidence_span: {"source_cache": "artifacts/chromium-research/16339278.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657", "start_char": 0, "end_char": 1949, "text_sha256": "57c07800ec80a0386c1c510fe0bd73bc5ebf196541580a5255565f8deafde657"} [chromium-p16339278] Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. (2006). https://pubmed.ncbi.nlm.nih.gov/16339278/ DOI: 10.1210/me.2005-0255

evidence_span

{"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"}

experimental_model

Three-month supplementation and acute muscle insulin-signaling experiment

exposure

Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups

limitations

Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male JCR:LA-cp obese and lean rats

plain_language

The signaling protein responded more strongly without more of it being present.

primary_references

[chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

tissue_or_cell_type

Vastus lateralis skeletal muscle

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 419–430

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-month supplementation and acute muscle insulin-signaling experiment · source_derived_draft · unverified_draft

### chromium-rat-irs1-phosphorylation In obese insulin-resistant rats, chromium picolinate increased insulin-stimulated IRS-1 phosphorylation without increasing IRS protein abundance. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The signaling protein responded more strongly without more of it being present. organism: Male JCR:LA-cp obese and lean rats tissue_or_cell_type: Vastus lateralis skeletal muscle experimental_model: Three-month supplementation and acute muscle insulin-signaling experiment limitations: Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study. exposure: Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups evidence_span: {"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"} [chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

evidence_span

{"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"}

experimental_model

Three-month supplementation and acute muscle insulin-signaling experiment

exposure

Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups

limitations

Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male JCR:LA-cp obese and lean rats

plain_language

Another downstream insulin-signaling step became more active.

primary_references

[chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

tissue_or_cell_type

Vastus lateralis skeletal muscle

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 432–443

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-month supplementation and acute muscle insulin-signaling experiment · source_derived_draft · unverified_draft

### chromium-rat-pi3k-activity Chromium picolinate increased insulin-stimulated PI3K activity in muscle from the obese rats without increasing PI3K protein abundance. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Another downstream insulin-signaling step became more active. organism: Male JCR:LA-cp obese and lean rats tissue_or_cell_type: Vastus lateralis skeletal muscle experimental_model: Three-month supplementation and acute muscle insulin-signaling experiment limitations: Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study. exposure: Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups evidence_span: {"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"} [chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

evidence_span

{"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"}

experimental_model

Three-month supplementation and acute muscle insulin-signaling experiment

exposure

Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups

limitations

Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male JCR:LA-cp obese and lean rats

plain_language

A protein that can oppose insulin signaling was reduced in this rat model.

primary_references

[chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

tissue_or_cell_type

Vastus lateralis skeletal muscle

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 445–456

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-month supplementation and acute muscle insulin-signaling experiment · source_derived_draft · unverified_draft

### chromium-rat-ptp1b-response Obese rats receiving chromium picolinate had lower muscle PTP1B abundance and lower activity after correction for protein content. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A protein that can oppose insulin signaling was reduced in this rat model. organism: Male JCR:LA-cp obese and lean rats tissue_or_cell_type: Vastus lateralis skeletal muscle experimental_model: Three-month supplementation and acute muscle insulin-signaling experiment limitations: Model-specific supplementation. Lower phosphatase protein and activity do not prove direct chromium binding to PTP1B. Different results from cultured adipocytes are contextual, not a reason to erase either study. exposure: Chromium picolinate supplying approximately 80 µg Cr/kg/day; small obese and lean treatment groups evidence_span: {"source_cache": "artifacts/chromium-research/16424121.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119", "start_char": 0, "end_char": 1734, "text_sha256": "b0fa1d0917ec9cf4f3d309f2e9eb0e2b498e083ed1ff881b8f8df94a3cbe8119"} [chromium-p16424121] Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. (2006). https://pubmed.ncbi.nlm.nih.gov/16424121/ DOI: 10.1093/jn/136.2.415

evidence_span

{"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"}

experimental_model

Radiolabeled-compound whole-body counting in rats and a human volunteer

exposure

Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate

limitations

Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat and human; species-specific results retained

plain_language

Absorption differed between humans and rats; the rat percentage should not be assigned directly to people.

primary_references

[chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5

tissue_or_cell_type

Intestinal uptake, urine and whole-body retention

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 133–144

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Radiolabeled-compound whole-body counting in rats and a human volunteer · source_derived_draft · unverified_draft

### chromium-species-bioavailability Apparent absorption in the human comparison was about 0.8–1%, higher than the 0.04–0.24% range across the tested rat complexes. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Absorption differed between humans and rats; the rat percentage should not be assigned directly to people. organism: Rat and human; species-specific results retained tissue_or_cell_type: Intestinal uptake, urine and whole-body retention experimental_model: Radiolabeled-compound whole-body counting in rats and a human volunteer limitations: Human component was a volunteer comparison, not a large population trial. Apparent absorption, absorbed amount before early urinary loss and seven-day retention are different quantities. exposure: Oral 51Cr-labeled supplement complexes; human intraindividual comparison of picolinate and phenylalaninate evidence_span: {"source_cache": "artifacts/chromium-research/22814636.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6", "start_char": 0, "end_char": 1673, "text_sha256": "392f4199c0cee925fff5f02ee9ce7d12047f9be5d278a55d09da0a3bb707c4b6"} [chromium-p22814636] Bioavailability of chromium(III)-supplements in rats and humans. (2012). https://pubmed.ncbi.nlm.nih.gov/22814636/ DOI: 10.1007/s10534-012-9571-5

evidence_span

{"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"}

experimental_model

Four-arm randomized supplementation trial; 92 participants

exposure

Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo

limitations

Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with type 2 diabetes

plain_language

The reported HOMA-IR pattern did not translate into a demonstrated HbA1c improvement.

primary_references

[chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

tissue_or_cell_type

Blood glycemia, HOMA-IR and TNF-alpha

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 679–690

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Four-arm randomized supplementation trial; 92 participants · source_derived_draft · unverified_draft

### chromium-vitd-hba1c-null HbA1c, fasting glucose and the lipid profile did not change significantly across the study’s groups. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The reported HOMA-IR pattern did not translate into a demonstrated HbA1c improvement. organism: Human with type 2 diabetes tissue_or_cell_type: Blood glycemia, HOMA-IR and TNF-alpha experimental_model: Four-arm randomized supplementation trial; 92 participants limitations: Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested. exposure: Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo evidence_span: {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"} [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

evidence_span

{"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"}

experimental_model

Four-arm randomized supplementation trial; 92 participants

exposure

Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo

limitations

Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with type 2 diabetes

plain_language

The chromium-containing groups avoided the increase seen in other arms of this trial.

primary_references

[chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

tissue_or_cell_type

Blood glycemia, HOMA-IR and TNF-alpha

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 653–664

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Four-arm randomized supplementation trial; 92 participants · source_derived_draft · unverified_draft

### chromium-vitd-homa HOMA-IR rose in the placebo and vitamin-D3-only groups but was controlled in the chromium and chromium-plus-vitamin-D3 groups. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The chromium-containing groups avoided the increase seen in other arms of this trial. organism: Human with type 2 diabetes tissue_or_cell_type: Blood glycemia, HOMA-IR and TNF-alpha experimental_model: Four-arm randomized supplementation trial; 92 participants limitations: Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested. exposure: Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo evidence_span: {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"} [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

evidence_span

{"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"}

experimental_model

Four-arm randomized supplementation trial; 92 participants

exposure

Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo

limitations

Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Human with type 2 diabetes

plain_language

The inflammatory marker changed in several active-treatment groups; this does not establish why HOMA-IR differed.

primary_references

[chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

tissue_or_cell_type

Blood glycemia, HOMA-IR and TNF-alpha

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 666–677

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Four-arm randomized supplementation trial; 92 participants · source_derived_draft · unverified_draft

### chromium-vitd-tnf TNF-alpha decreased in the vitamin-D3, chromium and combined-treatment groups. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The inflammatory marker changed in several active-treatment groups; this does not establish why HOMA-IR differed. organism: Human with type 2 diabetes tissue_or_cell_type: Blood glycemia, HOMA-IR and TNF-alpha experimental_model: Four-arm randomized supplementation trial; 92 participants limitations: Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested. exposure: Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo evidence_span: {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"} [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

availability_state

machinery_impairment Imported condition classification; unverified.

evidence_span

{"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"}

experimental_model

Hyperinsulinemia model with AMPK silencing

exposure

Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA

limitations

Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat L6 skeletal muscle myotubes

plain_language

When AMPK was depleted, this transporter response to chromium picolinate was lost.

primary_references

[chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

tissue_or_cell_type

Cultured muscle plasma membrane and cortical actin

trigger_kind

machinery_impairment Imported condition classification; unverified.

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 393–404

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Hyperinsulinemia model with AMPK silencing · source_derived_draft · unverified_draft

### chromium-ampk-required-glut4 AMPK silencing abolished chromium picolinate’s protection against impaired GLUT4 regulation in hyperinsulinemic L6 myotubes. Condition category: machinery_impairment nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: When AMPK was depleted, this transporter response to chromium picolinate was lost. organism: Rat L6 skeletal muscle myotubes tissue_or_cell_type: Cultured muscle plasma membrane and cortical actin experimental_model: Hyperinsulinemia model with AMPK silencing limitations: Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment. exposure: Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA evidence_span: {"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"} [chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

availability_state

machinery_impairment Imported condition classification; unverified.

evidence_span

{"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"}

experimental_model

Hyperinsulinemia model with AMPK silencing

exposure

Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA

limitations

Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Rat L6 skeletal muscle myotubes

plain_language

The glucose-uptake benefit also depended on AMPK in this experiment.

primary_references

[chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

tissue_or_cell_type

Cultured muscle plasma membrane and cortical actin

trigger_kind

machinery_impairment Imported condition classification; unverified.

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 406–417

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Hyperinsulinemia model with AMPK silencing · source_derived_draft · unverified_draft

### chromium-ampk-required-uptake AMPK silencing abolished chromium picolinate’s protection against impaired glucose transport in the same L6 model. Condition category: machinery_impairment nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The glucose-uptake benefit also depended on AMPK in this experiment. organism: Rat L6 skeletal muscle myotubes tissue_or_cell_type: Cultured muscle plasma membrane and cortical actin experimental_model: Hyperinsulinemia model with AMPK silencing limitations: Cell-culture mechanism. The indexed abstract identifies AMPK depletion without resolving the targeted catalytic isoform; family-level identity is retained. This is not a dietary repletion or human treatment experiment. exposure: Chromium picolinate during chronic low-dose insulin exposure, followed by acute insulin response; AMPK siRNA evidence_span: {"source_cache": "artifacts/chromium-research/24725432.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4", "start_char": 0, "end_char": 1788, "text_sha256": "f172a147ded27e509e27d5bcc53ad6dc3e8b22b424ab021515b205ae29bccbc4"} [chromium-p24725432] Chromium enhances insulin responsiveness via AMPK. (2014). https://pubmed.ncbi.nlm.nih.gov/24725432/ DOI: 10.1016/j.jnutbio.2014.01.007

evidence_span

{"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"}

experimental_model

Six-group high-fat-diet supplementation experiment

exposure

42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure

limitations

No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Sprague-Dawley rats

plain_language

This combination changed GLUT1 abundance in the rat experiment; the independent contribution of chromium was not isolated.

primary_references

[chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

tissue_or_cell_type

Brain, liver and systemic metabolism

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 718–729

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-group high-fat-diet supplementation experiment · source_derived_draft · unverified_draft

### chromium-biotin-rat-glut1 The chromium-histidinate-plus-biotin condition gave the highest reported GLUT1 protein levels among the compared high-fat-diet interventions in brain and liver. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This combination changed GLUT1 abundance in the rat experiment; the independent contribution of chromium was not isolated. organism: Male Sprague-Dawley rats tissue_or_cell_type: Brain, liver and systemic metabolism experimental_model: Six-group high-fat-diet supplementation experiment limitations: No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped. exposure: 42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure evidence_span: {"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"} [chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

evidence_span

{"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"}

experimental_model

Six-group high-fat-diet supplementation experiment

exposure

42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure

limitations

No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Sprague-Dawley rats

plain_language

This combination changed GLUT3 abundance in the rat experiment; the independent contribution of chromium was not isolated.

primary_references

[chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

tissue_or_cell_type

Brain, liver and systemic metabolism

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 731–742

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-group high-fat-diet supplementation experiment · source_derived_draft · unverified_draft

### chromium-biotin-rat-glut3 The chromium-histidinate-plus-biotin condition gave the highest reported GLUT3 protein levels among the compared high-fat-diet interventions in brain and liver. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This combination changed GLUT3 abundance in the rat experiment; the independent contribution of chromium was not isolated. organism: Male Sprague-Dawley rats tissue_or_cell_type: Brain, liver and systemic metabolism experimental_model: Six-group high-fat-diet supplementation experiment limitations: No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped. exposure: 42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure evidence_span: {"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"} [chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

evidence_span

{"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"}

experimental_model

Six-group high-fat-diet supplementation experiment

exposure

42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure

limitations

No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Sprague-Dawley rats

plain_language

This combination changed IRS-1 abundance in the rat experiment; the independent contribution of chromium was not isolated.

primary_references

[chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

tissue_or_cell_type

Brain, liver and systemic metabolism

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 744–755

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-group high-fat-diet supplementation experiment · source_derived_draft · unverified_draft

### chromium-biotin-rat-irs1 The chromium-histidinate-plus-biotin condition gave the highest reported IRS-1 protein levels among the compared high-fat-diet interventions in brain and liver. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This combination changed IRS-1 abundance in the rat experiment; the independent contribution of chromium was not isolated. organism: Male Sprague-Dawley rats tissue_or_cell_type: Brain, liver and systemic metabolism experimental_model: Six-group high-fat-diet supplementation experiment limitations: No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped. exposure: 42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure evidence_span: {"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"} [chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

evidence_span

{"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"}

experimental_model

Six-group high-fat-diet supplementation experiment

exposure

42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure

limitations

No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped.

nutrient_topic

Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

organism

Male Sprague-Dawley rats

plain_language

This combination changed PPAR-gamma abundance in the rat experiment; the independent contribution of chromium was not isolated.

primary_references

[chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851

tissue_or_cell_type

Brain, liver and systemic metabolism

Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 757–768

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-group high-fat-diet supplementation experiment · source_derived_draft · unverified_draft

### chromium-biotin-rat-pparg The chromium-histidinate-plus-biotin condition gave the highest reported PPAR-gamma protein levels among the compared high-fat-diet interventions in brain and liver. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This combination changed PPAR-gamma abundance in the rat experiment; the independent contribution of chromium was not isolated. organism: Male Sprague-Dawley rats tissue_or_cell_type: Brain, liver and systemic metabolism experimental_model: Six-group high-fat-diet supplementation experiment limitations: No chromium-only group in this design. Protein abundance is not proof of a direct target or human cognitive benefit. Product supplied by Nutrition 21; compound-specific comparisons remain scoped. exposure: 42 rats; biotin alone or with chromium histidinate, picolinate or both; 12-week exposure evidence_span: {"source_cache": "artifacts/chromium-research/30680172.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2", "start_char": 0, "end_char": 1282, "text_sha256": "71e98d2ad542eca99d6726b7fb592f311b609e32c0b071375979fb1b79b632c2"} [chromium-p30680172] Effect of supplementing chromium histidinate and picolinate complexes along with biotin on insulin sensitivity and related metabolic indices in rats fed a high-fat diet. (2019). https://pubmed.ncbi.nlm.nih.gov/30680172/ DOI: 10.1002/fsn3.851